Interaction of Varenicline with Classic Antiseizure Medications in the Mouse Maximal Electroshock-Induced Seizure Model.

Piotr Bernat, Patrycjusz Kołodziejczyk, Jarogniew J Łuszczki, Mirosław Zagaja, Piotr Tutka

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Piotr BernatDepartment of Experimental and Clinical Pharmacology, University of Rzeszów, 35-310 Rzeszów, Poland.

Patrycjusz KołodziejczykDepartment of Experimental and Clinical Pharmacology, University of Rzeszów, 35-310 Rzeszów, Poland.

Jarogniew J ŁuszczkiDepartment of Occupational Medicine, Medical University of Lublin, 20-059 Lublin, Poland.ORCID 0000-0002-3059-0393

Mirosław ZagajaIsobolographic Analysis Laboratory, Institute of Rural Health, 20-090 Lublin, Poland.

Piotr TutkaDepartment of Experimental and Clinical Pharmacology, University of Rzeszów, 35-310 Rzeszów, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Varenicline (VAR) is a partial agonist of brain α4β2 nicotinic acetylcholine receptors recommended as a first line pharmacotherapy for smoking cessation. The aim of this study was to examine whether VAR affects the protective activity of four classic antiseizure medications, i.e., carbamazepine (CBZ), phenobarbital (PB), phenytoin (PHT), and valproate (VPA) on maximal electroshock (MES)-induced seizures, which may serve as an experimental model of human-generalized tonic-clonic seizures in mice. VAR administered intraperitoneally (i.p.) at a subthreshold dose of 0.5 mg/kg decreased the protective activity of CBZ against MES-induced convulsions, increasing its median effective dose (ED50) from 10.92 ± 1.0 to 18.15 ± 1.73 mg/kg (

Indexed as

AnticonvulsantsSeizuresAnimalsBrainCarbamazepineDisease Models, AnimalDose-Response Relationship, DrugElectroshockHumansMicePhenobarbitalPhenytoinValproic AcidVareniclineAnticonvulsantsCarbamazepinePhenobarbitalPhenytoinValproic AcidVareniclineantiseizure medicationscarbamazepineepilepsymaximal electroshocksmoking cessationvarenicline

Identifiers

PMID36768937

DOI10.3390/ijms24032616

PMCPMC9916719

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.